Exploring CAR-T Cell Therapy as a Treatment for Multiple Myeloma

Multiple myeloma, a cancer of plasma cells in the bone marrow, has long been a challenging condition to treat due to its complex nature and tendency to relapse. Over the years, therapies have evolved, but many patients still experience limited long-term remission. In recent years, one of the most promising advancements has been the development of Chimeric Antigen Receptor T-cell (CAR-T) therapy, a revolutionary form of immunotherapy.
FOR MORE INFORMATION CLICK HERE ➖
https://www.edhacare.com/treatments/cancer/car-t-cell-therapy
CAR-T therapy involves modifying a patient’s own T-cells to better recognize and attack cancer cells. For multiple myeloma, this typically involves targeting specific antigens, like BCMA (B-cell maturation antigen).